About Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1
Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 (GPIHBP1) is a protein
from Homo sapiens identified by UniProt accession
Q8IV16, 184 residues long.
MolForge cross-references it against 0 known binders and
119 disease associations.
Target properties
| Protein name | Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 |
|---|
| UniProt accession | Q8IV16 |
|---|
| Gene | GPIHBP1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 184 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (119)
Diseases linked to this target (Open Targets).
- Hyperlipoproteinemia type 1 · score 0.79
- familial chylomicronemia syndrome · score 0.68
- high density lipoprotein cholesterol measurement · score 0.36
- familial lipoprotein lipase deficiency · score 0.35
- apolipoprotein A 1 measurement · score 0.32
- triglyceride measurement · score 0.27
- lung adenocarcinoma · score 0.25
- cutaneous melanoma · score 0.23
- alcohol drinking · score 0.22
- alcohol consumption measurement · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q8IV16-F1 | alphafold | PREDICTED | 73.35 | — |
Amino-acid sequence (184 residues)
MKALGAVLLA LLLFGRPGRG QTQQEEEEED EDHGPDDYDE EDEDEVEEEE TNRLPGGRSR VLLRCYTCKS LPRDERCNLT QNCSHGQTCT TLIAHGNTES GLLTTHSTWC TDSCQPITKT VEGTQVTMTC CQSSLCNVPP WQSSRVQDPT GKGAGGPRGS SETVGAALLL NLLAGLGAMG ARRP
Explore Glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets